These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7865386)

  • 21. Treatment of systemic sclerosis.
    Wigley FM
    Curr Opin Rheumatol; 1992 Dec; 4(6):878-86. PubMed ID: 1457284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Localized and systemic scleroderma.
    Hawk A; English JC
    Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of systemic sclerosis.
    Steen VD
    Am J Clin Dermatol; 2001; 2(5):315-25. PubMed ID: 11721650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study.
    Wigley FM; Wise RA; Seibold JR; McCloskey DA; Kujala G; Medsger TA; Steen VD; Varga J; Jimenez S; Mayes M; Clements PJ; Weiner SR; Porter J; Ellman M; Wise C; Kaufman LD; Williams J; Dole W
    Ann Intern Med; 1994 Feb; 120(3):199-206. PubMed ID: 7506013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E; Virgilio S; Ghirardi R; Martinelli M
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of severe scleroderma with long-term extracorporeal photopheresis.
    Krasagakis K; Dippel E; Ramaker J; Owsianowski M; Orfanos CE
    Dermatology; 1998; 196(3):309-15. PubMed ID: 9621138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of scleroderma.
    Sapadin AN; Fleischmajer R
    Arch Dermatol; 2002 Jan; 138(1):99-105. PubMed ID: 11790173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Points to consider-Raynaud's phenomenon in systemic sclerosis.
    Cutolo M; Smith V; Furst DE; Khanna D; Herrick AL
    Rheumatology (Oxford); 2017 Sep; 56(suppl_5):v45-v48. PubMed ID: 28992170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evidence-based therapy of systemic sclerosis].
    Genth E
    Z Rheumatol; 2001 Dec; 60(6):464-8. PubMed ID: 11826742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis).
    Enomoto DN; Mekkes JR; Bossuyt PM; Yong SL; Out TA; Hoekzema R; de Rie MA; Schellekens PT; ten Berge IJ; de Borgie CA; Bos JD
    J Am Acad Dermatol; 1999 Dec; 41(6):915-22. PubMed ID: 10570373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.
    Belch JJ; Capell HA; Cooke ED; Kirby JD; Lau CS; Madhok R; Murphy E; Steinberg M
    Ann Rheum Dis; 1995 Mar; 54(3):197-200. PubMed ID: 7538285
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
    Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of infrared thermography as an endpoint in therapeutic trials of Raynaud's phenomenon and systemic sclerosis.
    Pauling JD; Shipley JA; Harris ND; McHugh NJ
    Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S103-15. PubMed ID: 22691218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS; Porter JM; Smith EA; Belch J; Simms MH
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.